Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy

NCT01177735 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT01177735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01177735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy
Lead sponsor
University of Arkansas
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
September 30, 2013
Enrollment
71 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma